WHO ICTRP trial
A Phase 1b, open-label, dose-finding study of CC-90010 in combination with…
NL-OMON54644 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54644 |
|---|---|
| Public title | A Phase 1b, open-label, dose-finding study of CC-90010 in combination with temozolomide with or without radiation therapy in subjects with newly diagnosed glioblastoma |
| Scientific title | A Phase 1b, open-label, dose-finding study of CC-90010 in combination with temozolomide with or without radiation therapy in subjects with newly diagnosed glioblastoma - CC-90010-GBM-002 |
| Primary sponsor | Celgene Corporation |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | Italy;Netherlands;Spain |
| Conditions | Glioblastoma Glioma;10029211;Glioblastoma;Glioma |
| Interventions | Celgene will supply CC-90010 as formulated tablets for oral administration. TMZ will be prescribed, sourced and administered per package insert locally as standard of care. Study treatment may be discontinued if there is evidence of disease… |
| Registration date | Mar 8, 2023 |
| Target size | 36 |
| Secondary IDs | 2019-004122-25;NL72132.056.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: